|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues: | |||||
| Finance receivable interest income, including fees | |||||
| Pharmaceutical development | |||||
| Other | |||||
| Total revenues | |||||
| Costs and expenses: | |||||
| Provision for (benefit from) credit losses | |||||
| Loss on impairment of intangible assets | |||||
| Impairment of goodwill | |||||
| Loss on impairment | |||||
| Loss on disposal of inventory | |||||
| Interest expense | |||||
| Pharmaceutical manufacturing, research and development expense | |||||
| Change in fair value of acquisition-related contingent consideration | |||||
| Depreciation and amortization expense | |||||
| General and administrative expense | |||||
| Income from operations | |||||
| Other income (expense), net | |||||
| Unrealized net gain on warrants | |||||
| Unrealized net loss on equity securities | |||||
| Realized loss from sale of investments | |||||
| Foreign currency transaction gain (loss) | |||||
| Income before income tax benefit | |||||
| Net gain on exercise and cancellation of warrants | |||||
| Loss on sale of assets | |||||
| Gain on sale of business | |||||
| Net loss on marketable investments | |||||
| Realized gain on early payment of finance receivables | |||||
| Gain (loss) on revaluation of finance receivables | |||||
| Realized and unrealized foreign currency transaction gains (losses) | |||||
| Income before income tax expense | |||||
| Income tax expense | |||||
| Net income (loss) | |||||
| Net income (loss) per share | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted average shares outstanding | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
Loading...
